Pacira BioSciences Reports Record Revenue of $135.6 Million for the Second Quarter of 2021
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Pacira Pharmaceuticals (PCRX) PT Lowered to $66 at BMO Capital
August 5, 2021 12:41 PM EDTBMO Capital analyst Gary Nachman lowered the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $66.00 (from $70.00) while maintaining a Market Perform rating.
The analyst commented, "Exparel had solid 2Q (preannounced 7/13), and PCRX is optimistic strong momentum should continue in 2H21 with... More
Pacira Pharma (PCRX) Tops Q2 EPS by 8c
August 3, 2021 8:08 AM EDTPacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.77, $0.08 better than the analyst estimate of $0.69. Revenue for the quarter came in at $135.6 million versus the consensus estimate of $128.01 million.
Financial Guidance:
The companys net product sales were negatively impacted by the COVID-19 pandemic in 2020 due to the... More
